Drug Trial Radar · NCT07755904
BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Sep 2, 2026
Primary completion
Oct 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Braveheart Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this trial is to find out whether BHB-1893 works better than metoprolol in adults with symptoms of obstructive hypertrophic cardiomyopathy (oHCM). The trial includes adults who are currently being treated for oHCM or who have not yet been treated.
Conditions
- Cardiomyopathy, Hypertrophic Obstructive
Interventions
BHB-1893Drug
Tablets for oral use
MetoprololDrug
Capsules for oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)Time frame: Baseline, Week 24
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
LIONHEART-HCM Site 0120
Burlington, Massachusetts · Recruiting
LIONHEART-HCM Site 0107
Manhasset, New York · Recruiting
LIONHEART-HCM Site 0126
Rock Hill, South Carolina · Recruiting
LIONHEART-HCM Site 0121
Plano, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.